Your browser doesn't support javascript.
loading
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa, Teruhito; Yamamura, Ryosuke; Ohta, Kensuke; Kaneko, Hitomi; Imada, Kazunori; Nakaya, Aya; Fuchida, Shin-Ichi; Shibayama, Hirohiko; Matsuda, Mitsuhiro; Shimazu, Yutaka; Adachi, Yoko; Kosugi, Satoru; Uchiyama, Hitoji; Tanaka, Hirokazu; Hanamoto, Hitoshi; Shimura, Yuji; Kanda, Junya; Onda, Yoshiyuki; Uoshima, Nobuhiko; Yagi, Hideo; Yoshihara, Satoshi; Hino, Masayuki; Shimazaki, Chihiro; Takaori-Kondo, Akifumi; Kuroda, Junya; Matsumura, Itaru; Kanakura, Yuzuru; Nomura, Shosaku.
Afiliación
  • Takakuwa T; Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Yamamura R; Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Ohta K; Hematology Ohta Clinic, Shinsaibashi, Osaka, Japan.
  • Kaneko H; Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Imada K; Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Nakaya A; Division of Hematology, First Department of Internal Medicine, Kansai Medical University Medical Center, Hirakata, Japan.
  • Fuchida SI; Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
  • Shibayama H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Matsuda M; Department of Hematology, PL General Hospital, Tondabayashi, Japan.
  • Shimazu Y; Department of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
  • Adachi Y; Department of Internal Medicine, JCHO Kobe Central Hospital, Kobe, Japan.
  • Kosugi S; Department of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Toyonaka, Japan.
  • Uchiyama H; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
  • Tanaka H; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Hanamoto H; Department of Hematology, Kindai University Nara Hospital, Ikoma, Japan.
  • Shimura Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Kanda J; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Onda Y; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Uoshima N; Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
  • Yagi H; Department of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
  • Yoshihara S; Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Hino M; Department of Hematology, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Shimazaki C; Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
  • Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Matsumura I; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Kanakura Y; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Nomura S; Division of Hematology, First Department of Internal Medicine, Kansai Medical University Medical Center, Hirakata, Japan.
Eur J Haematol ; 106(4): 555-562, 2021 Apr.
Article en En | MEDLINE | ID: mdl-33476404
OBJECTIVES: This study aimed to investigate real-world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM). METHODS: We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database. RESULT: At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)-based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression-free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide-refractory patients had significantly lower PFS than lenalidomide-sensitive patients, who were comparable to TOURMALINE-MM1 study. The patients with IgG type had significantly better PFS and OS than those with non-IgG type. CONCLUSION: This study presents the largest real-world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE-MM1 study, and IRd showed poor efficacy, especially in the non-IgG type and lenalidomide-refractory patients with RRMM.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido